Each year, the FOYA program recognizes pharmaceutical manufacturing projects that use new and innovative technologies while reducing production costs of quality medicines. This year the program named the US Flu Cell Culture Facility at the Novartis Campus in Holly Springs, North Carolina as the winner. The facility uses a ground breaking technology to manufacture seasonal and pandemic influenza vaccines. The judges were impressed by the creative solution of containment convertibility that allows the facility to operate at lower levels to reduce costs, but maintain the capability of running at higher levels if need be.
Jacobs was responsible for design services, engineering, procurement and construction management for the facility. Jacobs Group Vice President Chris Nagel commented that, “It was an honor to work alongside Novartis and help meet their vaccine manufacturing needs for patients worldwide. We appreciate the trust they place in us and are very pleased that we were able to contribute to this award-winning project.”